---
title: "GlucoTrack Faces Multiple Nasdaq Deficiency Notices, Delisting Risk"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286622533.md"
description: "GlucoTrack (GCTK) faces delisting risk after receiving multiple deficiency notices from Nasdaq. The first notice, dated May 11, 2026, indicated non-compliance with the $1.00 minimum bid price requirement. A second notice on May 15 cited insufficient stockholders' equity below $2.5 million. The company plans to request a hearing by May 18 to address these issues. Spark's AI Analyst rates GCTK as Neutral due to weak financial performance and bearish technicals, despite some positive corporate milestones."
datetime: "2026-05-15T22:52:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286622533.md)
  - [en](https://longbridge.com/en/news/286622533.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286622533.md)
---

# GlucoTrack Faces Multiple Nasdaq Deficiency Notices, Delisting Risk

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

GlucoTrack ( (GCTK) ) has issued an announcement.

On May 11, 2026, GlucoTrack received a Nasdaq Staff Determination letter stating that its shares no longer met the $1.00 minimum bid price requirement, prompting Nasdaq staff to move toward delisting the stock from The Nasdaq Capital Market. The company plans to request a hearing by May 18, 2026, which will temporarily halt any delisting actions while it presents a plan to restore compliance with the bid price rule.

On May 15, 2026, Nasdaq issued a second notice after GlucoTrack’s Form 10-Q for the quarter ended March 31, 2026, showed stockholders’ equity below the $2.5 million minimum and failure to meet alternative listing standards, creating an additional delisting trigger. The company intends to address this further deficiency at the upcoming hearing, but investors face heightened uncertainty because there is no assurance the panel will allow continued listing or that GlucoTrack can regain compliance with Nasdaq’s requirements.

**Spark’s Take on GCTK Stock**

According to Spark, TipRanks’ AI Analyst, GCTK is a Neutral.

The score is primarily constrained by weak financial performance (no meaningful revenue, ongoing large losses, negative equity, and persistent cash burn) and bearish technicals (below major moving averages with negative MACD). Positive corporate milestones (IDE filing and supportive published preclinical results) partially offset these risks, while valuation metrics are not very informative given the company’s loss-making profile.

To see Spark’s full report on GCTK stock, click here.

**More about GlucoTrack**

GlucoTrack, Inc. is a Nasdaq-listed medical technology company focused on diabetes-related products, with its common stock traded on The Nasdaq Capital Market. The company operates in a sector where maintaining exchange listing standards, including minimum bid price and stockholders’ equity thresholds, is critical for access to capital and investor confidence.

**Average Trading Volume:** 4,640,177

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $1.3M

For an in-depth examination of GCTK stock, go to TipRanks’ Overview page.

### Related Stocks

- [GCTK.US](https://longbridge.com/en/quote/GCTK.US.md)

## Related News & Research

- [Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | GCTK Stock News](https://longbridge.com/en/news/286471959.md)
- [Palatin to Begin Trading on Nasdaq Stock Exchange | PTN Stock News](https://longbridge.com/en/news/286812696.md)
- [Prediction market ‘watchdog’ launches six-figure ad campaign ahead of Senate hearing](https://longbridge.com/en/news/286796384.md)
- [Democrats preview how they’d go after the Ticketmaster settlement if they regain power](https://longbridge.com/en/news/286961406.md)
- [Judge Rules Partly In Favor Of Luigi Mangione At Key Pretrial Hearing](https://longbridge.com/en/news/286789955.md)